Announcement
08.02.2013
In accordance with section 27b of Consolidated Act about Securities Trading etc., we hereby issue a complete list of NeuroSearch announcements from January 2012 to 8 February 2013. All announcements are available under the IR section of the company's website: www.neurosearch.com.
| Date | No. | Title |
| 26.01.2012 | 01-12 | Notice convening Extraordinary General Meeting in NeuroSearch A/S |
| 10.02.2012 | 02-12 | NeuroSearch announces a change to the date of the Annual General Meeting 2012 |
| 10.02.2012 | 03-12 | NeuroSearch – Financial calendar for 2012 |
| 20.02.2012 | 04-12 | Report on Extraordinary General Meeting in NeuroSearch A/S |
| 22.02.2012 | 05-12 | Release date for the financial statements 2011 for NeuroSearch A/S and subsequent telephone conference |
| 28.02.2012 | 06-12 | NeuroSearch announces the company's Annual Report 2011 |
| 28.02.2012 | 07-12 | List of NeuroSearch announcements from January 2011 to February 2012 |
| 16.03.2012 | 08-12 | Notice convening the Annual General Meeting of NeuroSearch A/S |
| 10.04.2012 | 09-12 | NeuroSearch A/S provides update on the process to secure financing to complete the Huntexil® development programme |
| 10.04.2012 | 10-12 | Report on Annual General Meeting held in NeuroSearch A/S |
| 25.04.2012 | 11-12 | NeuroSearch A/S – Q1 report 2012 and update on the company's activities |
| 10.05.2012 | 12-12 | Major shareholder announcement / UBS AG |
| 14.05.2012 | 13-12 | Major shareholder announcement / UBS AG |
| 23.05.2012 | 14-12 | NeuroSearch advises of charges filed against the company for alleged share price manipulation in 2010 |
| 28.05.2012 | 15-12 | NeuroSearch A/S reports conclusions from the Multiple Ascending Dose study (MAD) with Huntexil® |
| 22.06.2012 | 16-12 | NeuroSearch advises of the Danish Medicines Agency's conclusion on the TIPO-1 tesofensine study inspection |
| 27.06.2012 | 17-12 | NeuroSearch A/S changes the Executive Management |
| 30.08.2012 | 18-12 | NeuroSearch A/S – Interim report for H1 2012 |
| 31.08.2012 | 19-12 | NeuroSearch A/S reports change of employee elected Board members |
| 31.08.2012 | 20-12 | NeuroSearch A/S signs agreements regarding transfer of research collaboration with Janssen Pharmaceutica, NV and other projects to Aniona |
| 27.09.2012 | 21-12 | NeuroSearch A/S and Teva Pharmaceutical Industries Ltd. sign Huntexil® asset transfer agreement conditional upon NeuroSearch shareholder approval |
| 27.09.2012 | 22-12 | Notice convening Extraordinary General Meeting in NeuroSearch A/S |
| 23.10.2012 | 23-12 | Report on Extraordinary General Meeting in NeuroSearch A/S |
| 25.10.2012 | 24-12 | NeuroSearch A/S closes the sale of Huntexil® to Teva Pharmaceutical Industries Ltd. and adjusts the expectations to the full-year result |
| 15.11.2012 | 25-12 | NeuroSearch A/S – Interim report for the period January-September 2012 |
| 10.12.2012 | 26-12 | Notice convening Extraordinary General Meeting in NeuroSearch A/S |
| 04.01.2013 | 01-13 | Report on Extraordinary General Meeting in NeuroSearch A/S |
| 08.01.2013 | 02-13 | NeuroSearch – Financial calendar for 2013 |
| 21.01.2013 | 03-13 | NeuroSearch A/S – Annual General Meeting 2013 |
| 28.01.2013 | 04-13 | NeuroSearch A/S reports change of employee elected Board member |
| 01.02.2013 | 05-13 | Release date for the financial statements 2012 for NeuroSearch A/S and subsequent telephone conference |
| 04.02.2013 | 06-13 | NeuroSearch A/S sells land and building |
| 08.02.2013 | 07-13 | NeuroSearch A/S – Annual Report 2012 |
René Schneider
CEO
Contact person
René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I. All drug candidates exert their effect in the central nervous system.
